CELAGENEX RESEARCH (INDIA) PRIVATE LIMITED

Business Overview

• Celagenex is a biotech/specialty-pharma group developing therapies for chronic lifestyle diseases, diabetes, cardiac conditions, stroke, Alzheimer's, neuropathies, using endogenous metabolites and bioavailability-enhancer technology
• Holds ~13 patents issued/filed globally.
• Celagenex Research (India) Pvt Ltd is the Indian entity — MCA filings classify it under management-consultancy / medical-sciences R&D, while commercial trackers describe its on-ground activity as pharmaceutical retail and distribution, i.e., it appears to run the India commercialisation/R&D arm of the Celagenex brand.
• Company is DPIIT-recognised as a startup.
• Source: celagenex.com, official site, describing the "Celagenex" technology platform and business, HQ address shown as San Ramon, California, thecompanycheck.com, India registry + business description.

Sector & Classification

CIN industry code 36997 (generic "other manufacturing n.e.c." MCA classification). Actual registered activity per registry filings: management consultancy activities and research/experimental development in medical sciences (pharma/biotech). Business-description sources classify it under pharmaceutical retail & distribution.

Directors & Key Management

GST Registrations

Primary/home-state GSTIN: 27AAICC4124A1Z7 (Maharashtra) — confirmed by 2 sources (knowyourgst.com, mastersindia.co): Active, Regular taxpayer, registered 05 Dec 2019, principal place of business 6th Floor Bellona, Hiranandani Estate, Thane (W), Maharashtra 400607, legal name matches exactly. Additional registrations found via aggregator search (single-source, not yet cross-verified on individual GSTIN pages): 24AAICC4124A1ZD (Gujarat, reg. 01 Jul 2021) and 36AAICC4124A1Z8 (Telangana, reg. 17 Feb 2020); one snippet also referenced a Uttar Pradesh registration, unconfirmed. PAN across all: AAICC4124A. Total registrations: at least 3, possibly 4 — count not fully reconciled across sources.

Financials

• FY2025, year ended 31 Mar 2025, standalone, as reported by commercial trackers, not sourced from a filed annual report/PDF:
• Revenue: ~₹156.68 crore, thecompanycheck, / "₹150–200 cr" band with +52.91% YoY growth (Tofler) — two sources agree directionally and roughly in magnitude, ~53% YoY growth
• Treated as confirmed-in-range.
• EBITDA / PAT / Net profit: not obtained, paywalled on both trackers.
• Net worth: Tofler reports a YoY change of "-238.4%" — a large negative swing, may indicate net worth turned negative or was sharply eroded
• Not corroborated by a second source, and absolute value not obtained. Flag as partial/unverified — needs a filed balance sheet to confirm.
• Borrowings: Tofler shows +34.8% YoY increase in borrowings
• However both Tofler and thecompanycheck separately state "no registered charges" on company assets — so any increased borrowing appears unsecured/related-party/inter-company rather than charge-backed. Total assets: +26.12% YoY (Tofler).
• Employees: 687 per EPFO data as of 06 Mar 2025, thecompanycheck, single source.
• No standalone vs consolidated distinction was disclosed; company is small enough that consolidated accounts are unlikely to apply.

Funding History

• No external/VC funding identified.
• A Tracxn snippet on the affiliated US "Celagenex" entity, San Ramon, CA; founded 2019 by Rajaram Samant, explicitly describes it as "unfunded" / "has not raised any funding yet." No funding data specific to the India entity was found.
• Company is DPIIT-recognised as a startup, thecompanycheck, which is a registration status, not a funding event.

Shareholding

• Not obtained — shareholding pattern/cap table is paywalled on Tofler and not disclosed by other sources checked. Directors identified (see above) but their individual shareholding percentages are not available in public tracker content.

Loans & Charges

• No registered charges — confirmed by 2 independent sources, Tofler, thecompanycheck: "company has no registered charges" / "None registered." Note the tension with Tofler's own reported +34.8% YoY borrowings increase (see financials) — likely unsecured debt.

Related Parties

• Strong circumstantial link, not a confirmed corporate-filing relationship, between Celagenex Research (India) Pvt Ltd and "Celagenex" the US entity based in San Ramon, California: both share the "Celagenex" brand/logo, and Tracxn attributes founding of the US Celagenex entity to Rajaram Samant, who is also a director of the Indian company.
• This reads as a common-founder / shared-brand group structure, India entity likely functioning as the R&D/commercialisation arm, US entity as IP/brand holder, but no MCA-filed related-party-transaction disclosure or formal parent-subsidiary registration was found to confirm the legal structure.
• Treat as partial/unconfirmed.

Legal & Compliance

• Indian Kanoon lists several proceedings involving the company, case titles/dates found via search aggregation, not verified against full judgment text:
• Celagenex Research India Pvt Ltd vs Pharmak & Anr — Delhi High Court, hearings/orders dated 30 May 2025 and 22 Dec 2025, — appears to be a commercial/IP dispute where Celagenex is plaintiff.
• Nugenesys Pharmaceuticals Pvt. Ltd. vs Celagenex Research (India) Pvt. Ltd. — Delhi High Court, orders dated 13 & 16 Jul 2026, — Celagenex as defendant in a separate commercial dispute.
• Celagenex Research India Private vs Deputy Controller of Patents and Designs — Bombay High Court, multiple orders, 20 Aug 2025, 17 Jan 2026, 29 Jan 2026, 26 Feb 2026, 23 Apr 2026, — appears to be a recurring patent-prosecution/appeal matter, consistent with the company's stated large patent portfolio.
• Case list is from search-snippet aggregation only; full case text and outcomes were not read and should be verified directly on indiankanoon.org before publishing specifics.

Competitive Landscape

• India-focused specialty/metabolic-disease and licensed-technology pharma peers, rough scale tags, revenue-band estimates, not verified against each company's own filings:
• 1. Eris Lifesciences — metabolic disease, diabetes/cardiac, focused, listed, much larger, ~₹1,800+ cr revenue.
• 2. USV Pvt Ltd — diabetes/cardiovascular specialty pharma, large private company, ~₹3,000+ cr revenue.
• 3. Themis Medicare — specialty/licensed-technology pharma, listed, small-mid cap.
• 4. Marksans Pharma — listed, formulations manufacturer, mid-cap.
• 5. Curatio Healthcare — dermatology/specialty licensed-brand model, mid-size private.
• These are directional peer suggestions based on sector/business-model similarity, metabolic disease focus, licensing-driven specialty pharma, not a verified competitor set from a primary source.

Frequently Asked Questions

Sources

Tofler (tofler.in) — identity, capital, directors+DINs, financial % changes, charges, shareholding-page (no data); thecompanycheck.com — identity, financials (revenue/EPFO), business description, charges, director DIN cross-check; knowyourgst.com and mastersindia.co — primary GSTIN 27AAICC4124A1Z7 detail pages; DuckDuckGo HTML search (html.duckduckgo.com) used as a search-aggregation layer (not a primary source) to locate GSTIN list, additional director DIN, funding/Tracxn snippet, and Indian Kanoon case list; indiankanoon.org referenced via search snippets (direct site fetch failed with DNS error on www. subdomain); celagenex.com — official site for business overview, logo, and domain confirmation; falconebiz.com attempted but returned no company-specific data (generic landing page); zaubacorp.com and www.indiankanoon.org direct fetch both failed/blocked and were not used as sources of fact.